CRBP

Over the past six months, Corbus Pharmaceuticals reported Q4 2025 financial results, including a net loss of approximately $20.6 million. The company completed a public offering that raised $75 million, extending its cash runway into 2028. Encouraging Phase 1/2 data for CRB-701 in HNSCC and cervical cancer were presented at ESMO 2025, and abstracts featuring updated clinical data for CRB-701 were accepted for presentation at ASCO 2026. The company plans to host a KOL event at ASCO 2026 and expects to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026, anticipating data for CRB-701 in combination with Keytruda in first-line HNSCC patients in Q4 2026. Encouraging data from a Phase 1a study of CRB-913 was reported, and the last patient first visit in the CANYON-1 Phase 1b study of CRB-913 for obesity was announced, with the study on track for completion in summer 2026. Guggenheim initiated coverage with a "Buy" rating. The share price increased by 78.14% from May 7, 2025, to May 6, 2026, reaching $10.92. The 52-week high was $20.56, and the 52-week low was $6.33.